TINAVI Medical Technologies Co., Ltd. (Stock Code: 688277; hereinafter referred to as "TINAVI") is a high-tech enterprise focusing on the independent innovation, large-scale production, professional marketing and high-quality clinical application of orthopedic surgical robots and related technologies. It is also the first enterprise in China and the fifth enterprise in the world to obtain a medical robot registration license. In 2020, TINAVI was successfully listed on the STAR Market.

As a pioneer of medical robots in China, TINAVI has obtained more than 100 patents. It is a member unit of the National Robot Standardization Group of China and a supporting unit of both the National Local Joint Engineering Research Center of Medical Robots and the Beijing Medical Robot Industry Innovation Center. At the same time, it is also a board member of the China Association of Medical Equipment, a vice chairman unit of the Medical Robot Branch of the Chinese Society of Biomedical Engineering and the president unit of the Zhongguancun Medical Device Technical Innovation Alliance, a member enterprise of the China Robotic TOP10 Summit, and an innovation leadership enterprise of the Beijing Biomedical Industry Leapfrog Development Project (G20 Project). TINAVi has won the Second Prize of the 2015 National Science and Technology Progress Award and multiple national-, provincial- and ministerial-level honors, and hosts a postdoctoral research workstation.

TiRobots, the core products of TINAVI, can assist surgeons in accurately locating implants or surgical instruments. These products are widely used in spine and trauma orthopedic surgeries. With a clinical accuracy of less than 1mm, TiRobots can substantially reduce intraoperative radiation, improve surgical efficiency, simplify complex surgeries, standardize routine surgeries, and achieve minimally invasive surgeries and medical resources equality, thus helping surgeons to perform successful surgeries and benefit patients. By serving the "Healthy China" strategy, TiRobots help China to develop its own high-end medical equipment and contribute to a promising future of intelligent orthopedics. By the end of 2023 first quarter, the clinical application of TiRobot series orthopedic robots has covered more than 170 medical institutions, 30 provinces, autonomous regions and municipalities. The number of surgeries has exceeded 40,000 cases.